

Research Article: New Research | Cognition and Behavior

Sleep deprivation enhances conditioned place preference in an orexin receptor modulated manner

https://doi.org/10.1523/ENEURO.0283-20.2020

Cite as: eNeuro 2020; 10.1523/ENEURO.0283-20.2020

Received: 29 June 2020 Revised: 6 September 2020 Accepted: 12 September 2020

This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data.

Alerts: Sign up at www.eneuro.org/alerts to receive customized email alerts when the fully formatted version of this article is published.

Copyright © 2020 Bjorness and Greene

This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed.

- eNeuro Accepted Manuscript
- Manuscript Title (50 word maximum): Sleep deprivation enhances conditioned place
 preference in an orexin receptor modulated manner
- Abbreviated Title (50 character maximum): Sleep deprivation enhances cocaine CPP

5 3. List all Author Names and Affiliations in order as they would appear in the published 6 article:

- 7 Theresa E. Bjorness^{1,2*} and Robert W. Greene^{2,3,4}
- ¹Research Service, VA North Texas Health Care System, Dallas, TX 75126
- 9 ²Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas,
- 10 TX 75390-9111, USA
- 11 ³Department of Neuroscience, Peter O'Donnell Jr. Brain Institute, University of Texas
- 12 Southwestern Medical Center, Dallas, TX 75390-9111, USA
- ⁴International Institute for Integrative Sleep Medicine, University of Tsukuba, Tsukuba, 305 8577, Japan.
- 4. Author Contributions: TEB and RGW Designed Research; TEB Performed Research and
 Analyzed Data; TEB and RGW Wrote the paper
- 17 5. Correspondence should be addressed to (include email address):
- 18 theresa.bjorness@va.gov

19 20 21 22 23 24	6. Number of Figures: 5 7. Number of Tables: 4 8. Number of Multimedia: 0	 9. Number of words for Abstract: 127 10. Number of words for Significance Statement: 70 11. Number of words for Introduction: 570 12. Number of words for Discussion: 951
25 26 27 28 29	award number IK2BX002531 to TEB. Department of Veterans Affairs or the	was supported by the Department of Veterans Affairs, The contents do not represent the views of the U.S. 9 United States Government. We thank Shari Birnbaum and tions regarding experimental design and data

30 14. Conflict of Interest

- A. No (State 'Authors report no conflict of interest')
- 32 B. Yes (Please explain)

- 33 'Authors report no conflict of interest'34
- 35 **15. Funding sources:** This work was supported by the Department of Veterans Affairs, award
- 36 number IK2BX002531 to TEB.

37 Abstract: Drug addiction and withdrawal are characterized by sleep disruption, but the effects of 38 sleep disruption on these states are not well characterized. Sleep deprivation (SD) immediately 39 prior to the cocaine conditioning trials enhanced cocaine conditioned place preference (CPP) in 40 a dose-dependent manner (3, 8 mg/kg but not 15 mg/kg) in mice. SD immediately prior to the 41 post-conditioning test, also enhanced cocaine CPP preference in a dose dependent manner (8 42 mg/kg, but not 3, 15 mg/kg). Exposure to orexin-receptor antagonism (1 mg/kg SB334867, an 43 orexin 1 receptor antagonist) just prior to cocaine-conditioning trials or the post-conditioning 44 test, attenuated SD-enhanced preference. This suggests a potential therapeutic role for the 45 manipulation of the orexin system to mitigate drug seeking, especially in the context of sleep 46 loss prior to drug exposure.

Significance statement: Drugs of abuse, including cocaine, disturb sleep and sleep disturbance
has been implicated in probability of relapse; however, there have been few direct tests of sleep
disturbance on drug seeking behavior. Here, we show that acute (4h) sleep deprivation
enhances the rewarding properties of cocaine, a drug with high abuse potential. Furthermore,
antagonism of the orexin system, a neuromodulator involved in motivation-based arousal,
reduces this SD-induced enhancement of cocaine preference.

54 Introduction:

53

66

55 Cocaine, a psychostimulant with high abuse potential due to its strong reinforcing properties (Johanson et al., 1976; Bozarth and Wise, 1985), blocks monoaminergic transporters. Of these, 56 57 the dopamine transporter blockade is predominately responsible for reinforcement (Ritz et al., 58 1987). Cocaine is readily self-administered in non-humans to the point that unlimited access is 59 often fatal (Johanson et al., 1976; Bozarth and Wise, 1985). These appetitive properties can be 60 measured using conditioned place preference (CPP; Bardo and Bevins, 2000); an associative 61 learning task in which rewarding properties of stimuli are inferred based on time spent in a 62 context associated with a specific drug/stimuli (such as cocaine) relative to a neutral stimuli 63 (such as saline). As expected for a drug that produces reinforcement, animals show preference 64 for environments in which they have previously received cocaine (Mucha et al., 1982; Spyraki et 65 al., 1982).

67 Acute cocaine exposure potentiates arousal by increasing sleep latency and increasing the 68 amount of time in waking in a dose dependent manner (Dugovic et al., 1992; Knapp et al., 2007; 69 Bjorness and Greene, 2018). Increases in subsequent sleep compensate for the sleep loss to 70 the extent that there is no overall change in the amount of sleep/waking over the 24h period in 71 response to either acute (Bjorness and Greene, 2018) or to several days of repeated (Dugovic 72 et al., 1992) cocaine exposure. Non-compensated reductions in sleep are observed following 73 withdrawal from cocaine self-administration, with decreases in Non-Rapid Eye Movement Sleep 74 emerging one week into withdrawal, decreases in Rapid Eye Movement Sleep emerging one 75 day into withdrawal, and decreases in both persisting through three weeks of withdrawal (Chen 76 et al., 2015). Thus, chronic sleep disturbance emerges after more extensive exposure to 77 cocaine, while limited cocaine induces a sleep deprivation plus recovery response.

79 SD can influence drug use, as suggested by evidence that subjective sleep quality is a robust 80 predictor of relapse to alcohol consumption (Brower et al., 2001) and that lack of SWS time 81 recovery across abstinence is associated with relapse to cocaine use (Angarita et al., 2014). 82 Furthermore, subjective sleep disturbance is associated with cocaine relapse following 83 treatment in a large cohort study (Dolsen and Harvey, 2017). In rodents, chronic sleep 84 restriction can increase motivation for cocaine (i.e. the amount of work an animal will do to 85 obtain a cocaine reward) in a subset of animals (Puhl et al., 2013). SD also influences reward in 86 that SD increases preference for the stimulant methylphenidate in humans (Roehrs et al., 1999) 87 and induces preference to a low dose of amphetamine in mice (Berro et al., 2018). 88

89 The mechanism/s by which sleep loss could influence reward seeking have yet to be 90 determined; however, the peptide neuromodulator orexin [also known as hypocretin] shows 91 differential activity across sleep/waking states with increased activity during extended waking 92 (i.e. SD) compared to typical waking (Estabrooke et al., 2001; Yoshida et al., 2001), is 93 modulated by cocaine and other drugs of abuse (Thannickal et al., 2018; James et al., 2019), 94 and influences reward seeking (Hollander et al., 2012; Gentile et al., 2018) making it an 95 attractive candidate system. Furthermore, since orexin is heavily implicated in both maintenance 96 of arousal (Sakurai et al., 2010) and motivated behavior (James et al., 2017), it has been 97 hypothesized to integrate arousal and motivation (Tyree et al., 2018).

98

101

109

99 In the present study we tested the hypothesis that acute SD enhances cocaine CPP and that 100 the orexin system has an important role in this modulation.

102 Materials and Methods:

103 Animals: Adult male C57BL/6 mice were obtained from Charles River Laboratories. Mice were 104 assigned into groups (described below) and placed into cages atop a treadmill apparatus with 105 food and water available ad libitum in rooms with an ambient temperature of 22.0 +/- 1 $^{\circ}$ C and a 106 12:12 h light/dark cycle. All experiments were approved by the VA North Texas Health Care 107 System IACUC and were in accordance with recommendations in the Guide for Care and Use of Laboratory Animals (U.S. National Research Council). 108

110 Cocaine conditioned place preference:

111 An unbiased design was used with three chambered CPP boxes (Med Associates). These 112 boxes were unbiased in that there was no overall preference for either of the side chambers 113 which feature different wall and flooring patterns to make them easily distinguishable. First, mice 114 were given a pre-conditioning test in which they were placed into the center chamber (doors 115 open) and allowed to explore for 20 min. Mice were excluded if they showed an innate 116 preference for either side (as defined by >20% difference in percent time spent between sides) or if they spent more time in the center chamber than either side chamber. A subset of 117 118 "excluded" mice underwent a second pre-conditioning test using a different CPP box (featuring 119 different floor and wall patterns). These double pre-tested animals were divided evenly across 120 groups. Next, mice underwent four conditioning trials (doors closed) in which they received 121 cocaine (3, 8, or 15 mg/kg) or saline (vehicle control) with one, 30 min trial per day. Finally, mice 122 were given a 20 min post-conditioning test (doors open). Testing and conditioning trials

occurred between ZT4-ZT7 and were conducted under low light level to encourage exploration.
Time in each chamber was determined by IR beam break (automated) or video (manual). Based
on previous reports, preference is expected for the 8 mg/kg dose (Campbell et al., 2000) and for
the 15 mg/kg dose (Nomikos and Spyraki, 1988), but not for the 3 mg/kg dose (Zachariou et al.,
2001). While conditioning protocols vary, two trials are expected to be sufficient to support the
development of cocaine preference (McClung et al., 2005; Graham et al., 2009).

130 Cocaine CPP Study 1 (Figure 1A): For each cocaine dose (3, 8, 15 mg/kg), two groups of 131 animals were compared (group names are designated based on the sleep parameters [SD or 132 undisturbed {noSD}] before each set of conditioning trials [cocaine {Coc} or saline {Sal}]. Both 133 groups received cocaine and saline on alternating days. The experimental group of mice 134 underwent SD for 4 h immediately prior to cocaine conditioning trials and, on alternate days, 135 were undisturbed prior to saline conditioning trials (SD Coc, noSD Sal). The control group was 136 sleep deprived for 4 h immediately prior to the saline conditioning trials (noSD Coc, SD Sal) but 137 was undisturbed prior to the cocaine conditioning trials. An additional experiment was used to 138 test whether SD is sufficient to induce preference. Subjects received saline on both side 139 chambers with (SD Sal, noSD Sal) or without SD (noSD Sal, noSD Sal) prior to saline-140 conditioning trials on one side of the box. Animals were weighed prior to each conditioning trial. 141 There was no difference in pre-conditioning relative time values (side A – side B) between 142 groups for any of the doses (0 mg/kg, p=0.96; 3 mg/kg, p=0.98; 8 mg/kg, p=0.99; 15 mg/kg, 143 p=0.71).

145 *Cocaine CPP Study 2 (Figure 2A):* For each cocaine dose (3, 8, 15 mg/kg), two groups of 146 animals were compared (group names are designated based on the sleep parameters, [SD], or 147 undisturbed [noSD], before the post-conditioning test). Both groups received cocaine and saline 148 on alternating days. In this study the experimental group of mice was sleep deprived on only 149 one occasion, i.e. 4 h immediately prior to the post-test (**SD**), while a control group was 150 undisturbed (**noSD**). There was no difference in pre-conditioning relative time values between 151 groups for any of the doses (3 mg/kg, *p*=0.99; 8 mg/kg, *p*=0.73; 15 mg/kg, *p*=0.68).

153 Orexin-receptor antagonism during conditioning and SD-enhanced Cocaine CPP Study 3 154 (Figure 3A): Subsets of mice receiving 3 or 8 mg/kg cocaine were injected with the orexin 1 155 receptor antagonist (OX1R) SB 334867 (1 mg/kg [SB]) or vehicle [Veh] 15 min prior to the 156 conditioning trials (group names are designated based on sleep parameters and OX1R-157 antagonism status prior to each conditioning test). The experimental group was sleep deprived 158 for 4 h and given SB prior to cocaine conditioning trials (SD SB Coc, noSD Veh Sal), while a 159 control subset of mice was sleep deprived and given SB prior to the saline paired trials (noSD 160 Veh Coc, SD SB Sal). For the 8 mg/kg dose, a third subset of mice was injected with SB prior 161 to the cocaine paired trials but was not sleep deprived, serving as an OX1R antagonist-only 162 control (noSD SB Coc, noSD Veh Sal). There was no difference in pre-conditioning relative 163 time values between groups at either dose (3 mg/kg, p=0.9; 8mg/kg, p=0.99). SB 334867 was 164 chosen on the basis of its common use in addiction-related studies, while the cocaine doses 165 chosen were based on the doses in which there were significant group differences in Study 1 (3, 166 8 mg/kg).

OX1R antagonism after conditioning and SD-enhanced Cocaine CPP Study 4 (Figure 4A):
 Subsets of mice receiving 8 mg/kg cocaine were injected with SB 15 min prior to the post-test.
 The experimental group was sleep deprived for 4 h prior to receiving SB (SD SB), while the
 control group was undisturbed prior to receiving SB (noSD SB). There was no difference in pre conditioning relative time values between groups (*p*=0.98). The cocaine dose chosen was
 based on the dose in which there was a significant group difference in Study 2 (8 mg/kg).

174 Sleep deprivation: Mice were sleep deprived using the treadmill method (Bjorness et al., 2009) 175 in which waking is enforced through slow walking; the belt speed was ~3cm/s (for comparison 176 belt speeds of ~20 cm/s are used for exercise, Um et al., 2011). SD began early in the light 177 phase (ZT0-2) and concluded immediately before CPP conditioning or testing for a total of 4 h. 178 Food and water were available throughout the SD period. Four hours of sleep deprivation was 179 used since this duration reliably induces a homeostatic response as measured by an increase in 180 slow wave activity (SWA, 0.5-4.5 Hz) during slow wave sleep (Bjorness et al., 2018b). 181 Furthermore, this duration does not increase expression of glucocorticoid-related genes as 182 determined by transcriptome analysis of cortical tissue (Bjorness et al., 2020).

Drugs: Cocaine hydrochloride (Sigma Aldrich) was dissolved in sterile saline and injected in
 doses of 3, 8, or 15 mg/kg with a volume of ≤0.1ml. Sterile saline was used as the vehicle
 control. SB 334867 (Sigma Aldrich) was dissolved in DMSO then diluted in sterile water (10%
 DMSO). DMSO diluted with sterile water was used as the vehicle control.

189 Outcome measures: The main outcome measure for cocaine CPP was preference score which 190 was calculated as Preference (sec) = Post-conditioning test [side Atime- side Btime] - Pre-191 conditioning test [side Atime - side Btime] with A side conditioning in trials 1, 3 and B side in trials 192 2, 4. For Study 1 and 2, control and experimental groups were compared using one tailed 193 unpaired T tests (3, 8, or 15 mg/kg cocaine) or two tailed unpaired T test (0 mg/kg cocaine). For 194 Study 3 and 4, control and experimental groups were compared using two tailed unpaired T test 195 (3 mg/kg Study 3, 8 mg/kg Study 4) or one way ANOVA with Sidak correction for multiple 196 comparisons (8 mg/kg Study 4). One tailed T tests were used for comparisons in which there is 197 literature support for an effect of SD on preference outcomes, while two tailed T tests were used 198 for comparisons lacking direct literature support for an effect of SD on preference outcomes. 199 Additionally, pre-conditioning relative time values (time in side to be paired with cocaine – time 200 in side to be paired with saline) were also compared for each experiment to ensure equal 201 balancing (with respect to pre-conditioning preference time) of groups prior to cocaine exposure. 202 For comparison to a theoretical mean of 0, a two-tailed one sample t test was used; positive 203 values significantly different than 0 indicate preference. All statistical analyses were performed 204 using GraphPad prism. Values are given as average +/- standard error of the mean and 205 significance is set at p<0.05. For all studies, pre and post-conditioning relative values are shown 206 (Figure 1B, 2B, 3B, 4B) for the 8 mg/kg dose in order to illustrate variability between animals 207 within each group alongside the general pattern of increased time in the cocaine-paired side.

208

183

188

209 Results:

236

245

210 Cocaine CPP; Study 1: To examine the effects of SD on cocaine CPP we compared CPP in 211 experimental and control groups of mice. Both groups were alternately (every other day) 212 conditioned to cocaine and saline (Coc, Sal), however, the experimental group's cocaine 213 conditioning was preceded by 4 hours of SD (SD Coc, noSD Sal) whereas the control group's 214 saline conditioning was preceded by SD (noSD Coc, SD Sal) as illustrated in figure 1A. To 215 control for the potential effects of SD in the absence of cocaine conditioning, an additional two cohorts of mice received saline every day either with (SD Sal, noSD Sal) or without SD (noSD 216 217 Sal, noSD Sal). 218

219 As expected, most animals (8/12 noSD Coc, SD Sal, 12/12 SD Coc, noSD Sal) that received 220 the 8 mg/kg dose of cocaine showed an increase in the time spent in the cocaine-paired side, 221 tested after conditioning (Figure 1B); however, SD immediately prior to cocaine conditioning 222 trials resulted in an increase in time spent on the cocaine-paired side over animals experiencing 223 SD preceding saline (Figure 1C, Table 1). In the absence of SD, animals did not show any 224 preference for the 3mg/kg cocaine-conditioned side. In contrast, SD immediately prior to 225 cocaine conditioning trials induced preference to a 3 mg/kg dose of cocaine (Figure 1C; Table 226 1). SD did not influence preference to a 15 mg/kg dose of cocaine, a possible ceiling-like effect 227 (Figure 1C; Table 1). Controls (noSD Coc, SD Sal) showed preference at 15 mg/kg but not at 8 228 mg/kg, possibly due to high variability driven by one animal (not identified as an outlier when 229 using the ROUT method [GraphPad Prism]). SD in the absence of cocaine did not induce 230 preference (0 mg/kg, Figure 1C; Table 1).

Cocaine CPP; Study 2: To examine the effects of SD on cocaine CPP after conditioning has
 been established, cocaine-conditioned animals underwent SD for 4 hours immediately prior to
 the post-conditioning test. The control group was similarly conditioned but remained undisturbed
 prior to testing for CPP (Figure 2A).

237 As expected, most animals (n=9/13 noSD; 10/11 SD) that received the 8mg/kg dose of cocaine 238 showed an increase in the time spent in the cocaine-paired side from the pre-conditioning to 239 post-conditioning tests (Figure 2B). SD immediately prior to the post-conditioning test induced a 240 non-significant trend towards preference to a 3 mg/kg dose of cocaine (Figure 2C; Table 2) and 241 significantly increased preference to an 8 mg/kg dose of cocaine (Figure 2C; Table 2). There 242 was no difference in preference between groups to a 15 mg/kg dose of cocaine (Figure 2C; 243 Table 2), but the sleep deprived group showed a non-significant trend towards preference for 244 the cocaine-paired side.

246 OX1R antagonism during conditioning and SD-enhanced Cocaine CPP; Study 3: A previous 247 observation indicates that SB 334867 during conditioning attenuates cocaine CPP (Rao et al., 248 2013). To examine the effects of OX1R antagonism on SD-induced enhancement of cocaine 249 CPP, we compared CPP in an experimental and control group as in Study 1, except that 250 immediately following SD, but prior to each training session, animals received the OX1R 251 antagonist SB 334867 (SB) or vehicle (Veh) on alternating days (Figure 3A). To test for OX1R 252 antagonism effects in the absence of SD, SB 334867 was also given to cohort that did not 253 undergo SD.

255 In response to 8 mg/kg cocaine, all sleep deprived animals showed an increase in the time 256 spent on the cocaine-paired side; however, only a subset (6/11) of animals receiving OX1R 257 antagonism in the absence of SD showed this relative increase (Figure 3B). In contrast to the 258 observations of Study 1 in which SD induced cocaine CPP to a 3 mg/kg dose of cocaine, SB 259 334867 prevented this induction. Finally, SB 334867 prevented preference in the absence of SD 260 and blocked SD-induced enhancement of preference to a 8 mg/kg dose of cocaine as 261 determined by a lack of difference between groups; however SD animals treated with SB 262 334867 did show preference for the cocaine-paired side suggesting that SD-dependent 263 enhancement is reduced but not entirely prevented (Figure 3C; Table 3). 264

OX1R antagonism after conditioning and SD-enhanced Cocaine CPP; Study 4: Previous
observations indicate that SB after conditioning does not influence cocaine CPP (Sharf et al.,
2010; Sartor and Aston-Jones, 2012). The effect of OX1R antagonism together with SD on
cocaine CPP after establishment of conditioning was examined by comparing CPP in an
experimental and control group of mice as in Study 2, except that all animals received the OX1R
antagonist prior to the post-conditioning test (Figure 4A).

A similar majority of undisturbed or sleep deprived animals administered SB 334867 just prior to
the post-conditioning test, showed an increase in the time spent on the cocaine-paired side
(Figure 4B). The antagonism of OX1R after establishment of conditioning was sufficient to
prevent the SD-induced enhancement of cocaine CPP to an 8 mg/kg dose of cocaine (Figure
4C; Table 4).

278 Sleep deprivation shifts the cocaine CPP dose-response curve leftward in an orexin-influenced 279 manner: SD immediately prior to cocaine-conditioning trials shifts the preference dose-response 280 curve leftward (Figure 5A) which is consistent with an increasing sensitivity to the rewarding 281 properties of cocaine. However, OX1R antagonism immediately prior to the cocaine-282 conditioning trials reduces this shift (Figure 5B). An SD-related leftward shift in the dose 283 response curve is also apparent when SD occurs immediately prior to the post-conditioning test 284 (Figure 5C) and it is reduced by OX1R antagonism. Unexpectedly, OX1R antagonism in 285 undisturbed animals prior to the post-conditioning test [Study 4; noSD SB] led to preference 286 values similar to that of sleep deprived animals in the absence of OX1R antagonism [Study 2; 287 SD], thereby reversing the polarity of the effect of SD as determined by dividing the group 288 average preference score of the sleep deprived group by the group average preference score of 289 the undisturbed group (i.e. [Study 2, SD/noSD]; [Study 4, SD SB/noSD SB]). A score above 1 290 indicates that SD results in a higher relative preference score compared to the undisturbed 291 condition, while a score below 1 indicates that SD results in a lower relative preference score 292 compared to the undisturbed condition. Statistical comparisons across studies were not 293 performed because of data collection constraints (see discussion section) so these comparisons 294 are observational in nature and should be interpreted with caution.

295

254

271

277

Discussion: SD enhanced cocaine CPP in a dose-dependent manner resulting in a leftward shift
 in the dose-response curve, indicating SD increased the rewarding properties of cocaine. This

309

322

330

shift was more pronounced when SD occurred immediately prior to cocaine exposure compared
 to SD after cocaine conditioning was already established, consistent with a greater SD-induced
 enhancement of acquisition of preference than of its expression. OX1R antagonism reduced the
 SD-induced enhancement of both acquisition and expression.

303 On the low end of the dose-response curve, SD induced preference to a subthreshold dose of 304 cocaine, which is similar to a previously reported SD-dependent induction of preference to 305 subthreshold amphetamine (Berro et al., 2018), suggesting SD may increase sensitivity to 306 psychostimulants in general. On the high end of the dose-response curve, SD did not alter 307 preference to a sensitizing dose of cocaine, possibly due to a ceiling effect and/or, an aversive 308 effect elicited by higher doses of cocaine.

310 Most groups showed preference for the 8 mg/kg dose of cocaine, a dose in which preference is 311 expected (Campbell et al., 2000); however, animals sleep deprived prior to saline conditioning 312 trials (noSD Coc, SD Sal, Study 1) did not reach statistical significance for preference despite 313 the majority of animals showing an increase in time spent on the cocaine-paired side from the 314 pre to post-conditioning tests (8/12). This lack of preference is likely attributable to high 315 variability in preference scores relative to the group average (126.4 +/- 83.6) and is driven by a 316 single animal as can be seen in Figure 1B, though this animal does not qualify as an outlier. As 317 can be seen from the raw data plots with the 8 mg/kg dose across studies, most animals show 318 an increase in relative time in the cocaine-paired side from pre to post-conditioning, though not 319 all animals do so. We cannot explain the source of the individual differences, but these are 320 consistent with individual differences seen with locomotor sensitization to cocaine (Hooks et al., 321 1991; Allen et al., 2007) and cocaine self-administration (Glick et al., 1994; Griffin et al., 2007).

The ability of OX1R antagonism to reduce SD-induced enhancement of cocaine CPP is consistent with the well-known role of orexin in motivated behavior (James et al., 2017) and maintenance of arousal (Sakurai et al., 2010). Orexin neuronal activity increases during SD (Estabrooke et al., 2001) as does orexin release (Yoshida et al., 2001). Furthermore, orexin agonists promote cocaine self-administration (Espana et al., 2011), while antagonism of orexin activity can reduce reward behavior (Sartor and Aston-Jones, 2012; Rao et al., 2013, Shaw et al., 2017).

331 The SD-induced enhancement of cocaine CPP is consistent with previous studies in which SD 332 increases preference of methylphenidate in humans (Roehrs et al., 1999) and induces 333 preference to a low dose of amphetamine in rodents (Berro et al., 2018). However, there are 334 several additional studies that would be of interest in further delineating the ability of sleep loss 335 to influence reward behavior. First, thus far all studies have used stimulants so the 336 generalizability of the SD-induced enhancement of preference across drug class is unknown. 337 Additionally, the time course of this enhancement preference is unclear. A long term 338 enhancement of preference would likely be more relevant to the development of addiction than 339 if the SD-induced enhancement is quickly lost. Finally, it is unknown if SD-induced 340 enhancement of stimulant reward is sustained in drug experienced animals since existing 341 studies have included drug naïve rodents or non-dependent humans.

343 These studies had several limitations. First, Study 4 lacked a vehicle control group; a control 344 group of noSD SB was used for the experimental group SD SB in which the ability of OX1R-345 antagonism to counter SD-induced enhancement of cocaine CPP to an 8 mg/kg dose of cocaine 346 (from Study 2) was tested. DMSO was diluted in order to reduce the concentration below that 347 which behavioral effects are observed (Cavas et al., 2005). However, the effect of vehicle alone 348 on CPP expression was not determined so the possibility that SD-induced enhancement of 349 cocaine CPP was reduced by the vehicle cannot be excluded. Another limitation relates to the 350 lack of direct statistical comparisons across related studies (Study 1&3, Study 2&4) due to the 351 manner of data collection. Within each study, control and experimental animals were littermates 352 and data were collected concurrently across groups with multiple sets of control and 353 experimental animals collected for each study; however, there was a considerable time lag 354 between data collection of related studies. A superior design would have included concurrent 355 data collection for related studies so that these could be directly compared. Additionally, since 356 activity measures are not available for conditionings performed with all of the CPP boxes, we 357 cannot exclude a possibility that enhanced preference is associated with an increase in 358 locomotor activity; however, we have previously shown that acute SD does not influence the 359 magnitude of locomotor sensitization to cocaine (Bjorness and Greene, 2018b) so an SD-360 dependent increase in locomotor activity is not expected. Finally, the current experiments did 361 not include female subjects so it is unknown whether gender influences SD-enhancement of 362 cocaine CPP. 363

364 In conclusion, acute SD increases the rewarding properties of cocaine in a cocaine dose 365 dependent manner as measured by the CPP task which suggests that sleep loss may facilitate 366 the transition towards addiction. OX1R antagonism reduces this effect, suggesting a potential 367 therapeutic avenue for careful consideration as an aid in abstinence maintenance. Recently, 368 Suchting and colleagues provided preliminary proof-of-concept for use of orexin receptor 369 antagonism in individuals with cocaine use disorder (Suchting et al., 2020). Although the study 370 design precludes an assessment of the efficacy of a OX1R/OX2R antagonist, there is evidence 371 for its having improved objective sleep (actigraphy) and self-reported craving measures 372 (Cocaine Craving Questionnaire), suggesting the clinical relevance for our findings.

eNeuro Accepted Manuscript

386 Allen RM, Everett CV, Nelson AM, Gulley JM, Zahniser NR (2007) Low and high locomotor 387 responsiveness to cocaine predicts intravenous cocaine conditioned place preference in male 388 Sprague-Dawley rats. Pharmacol Biochem Behav 86:37-44. 389 390 Angarita GA, Canavan SV, Forselius E, Bessette A, Morgan PT (2014) Correlates of 391 polysomnographic sleep changes in cocaine dependence: self-administration and clinical 392 outcomes. Drug Alcohol Depend 143:173-180. 393 394 Bardo MT, Bevins RA (2000) Conditioned place preference: what does it add to our preclinical 395 understanding of drug reward? Psychopharmacology (Berl) 153:31-43. 396 397 Bardo MT, Rowlett JK, Harris MJ (1995) Conditioned place preference using opiate and 398 stimulant drugs: a meta-analysis. Neurosci Biobehav Rev 19:39-51. 399 400 Berro LF, Tufik SB, Frussa-Filho R, Andersen ML, Tufik S (2018) Sleep deprivation precipitates 401 the development of amphetamine-induced conditioned place preference in rats. Neurosci Lett 402 671:29-32. 403 404 Bjorness TE, Greene RW (2018) Dose response of acute cocaine on sleep/waking behavior in 405 mice. Neurobiol Sleep Circadian Rhythms 5:84-93. 406 407 Bjorness TE, Greene RW (2018b) Sleep deprivation alters the time course but not magnitude of 408 locomotor sensitization to cocaine. Sci Rep 8:17672. 409 410 Bjorness TE, Kelly CL, Gao T, Poffenberger V, Greene RW (2009) Control and function of the 411 homeostatic sleep response by adenosine A1 receptors. J Neurosci 29:1267-1276. 412 413 Bjorness TE, Kulkarni A, Rybalchenko V, Suzuki S, Bridges C, Harrington AJ, Cowan CW, 414 Takahashi JS, Konopka G, Greene RW (2020) An essential role for MEF2C in the cortical 415 response to loss of sleep. eLife, eLife 9:e58331. 416 417 Bozarth MA, Wise RA (1985) Toxicity associated with long-term intravenous heroin and cocaine 418 self-administration in the rat. JAMA 254:81-83. 419 420 Brower KJ, Aldrich MS, Robinson EA, Zucker RA, Greden JF (2001) Insomnia, self-medication, 421 and relapse to alcoholism. Am J Psychiatry 158:399-404. 422 423 Campbell JO, Wood RD, Spear LP (2000) Cocaine and morphine-induced place conditioning in 424 adolescent and adult rats. Physiol Behav 68:487-493. 425 426 Cavas M, Beltran D, Navarro JF (2005) Behavioural effects of dimethyl sulfoxide (DMSO): 427 changes in sleep architecture in rats. Toxicol Lett 157:221-232.

429 Chen B, Wang Y, Liu X, Liu Z, Dong Y, Huang YH (2015) Sleep Regulates Incubation of 430 Cocaine Craving. J Neurosci 35:13300-13310. 431 Dolsen MR, Harvey AG (2017) Life-time history of insomnia and hypersomnia symptoms as 432 433 correlates of alcohol, cocaine and heroin use and relapse among adults seeking substance use 434 treatment in the United States from 1991 to 1994. Addiction 112:1104-1111. 435 436 Dugovic C, Meert TF, Ashton D, Clincke GH (1992) Effects of ritanserin and chlordiazepoxide 437 on sleep-wakefulness alterations in rats following chronic cocaine treatment. 438 Psychopharmacology (Berl) 108:263-270. 439 440 Espana RA, Melchior JR, Roberts DC, Jones SR (2011) Hypocretin 1/orexin A in the ventral 441 tegmental area enhances dopamine responses to cocaine and promotes cocaine self-442 administration. Psychopharmacology (Berl) 214:415-426. 443 444 Estabrooke IV, McCarthy MT, Ko E, Chou TC, Chemelli RM, Yanagisawa M, Saper CB, 445 Scammell TE (2001) Fos expression in orexin neurons varies with behavioral state. J Neurosci 446 21:1656-1662. 447 448 Gentile TA, Simmons SJ, Barker DJ, Shaw JK, Espana RA, Muschamp JW (2018) Suvorexant, 449 an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of 450 cocaine. Addict Biol 23:247-255. 451 452 Glick SD, Raucci J, Wang S, Keller RW, Jr., Carlson JN (1994) Neurochemical predisposition to 453 self-administer cocaine in rats: individual differences in dopamine and its metabolites. Brain Res 454 653:148-154. 455 456 Graham DL, Krishnan V, Larson EB, Graham A, Edwards S, Bachtell RK, Simmons D, Gent LM, 457 Berton O, Bolanos CA, DiLeone RJ, Parada LF, Nestler EJ, Self DW (2009) Tropomyosin-458 related kinase B in the mesolimbic dopamine system: region-specific effects on cocaine reward. 459 Biol Psychiatry 65:696-701. 460 461 Hollander JA, Pham D, Fowler CD, Kenny PJ (2012) Hypocretin-1 receptors regulate the 462 reinforcing and reward-enhancing effects of cocaine: pharmacological and behavioral genetics evidence. Front Behav Neurosci 6:47. 463 464 465 Hooks MS, Jones GH, Smith AD, Neill DB, Justice JB, Jr. (1991) Individual differences in 466 locomotor activity and sensitization. Pharmacol Biochem Behav 38:467-470 467 468 James MH, Mahler SV, Moorman DE, Aston-Jones G (2017) A Decade of Orexin/Hypocretin 469 and Addiction: Where Are We Now? Curr Top Behav Neurosci 33:247-281. 470

James MH, Stopper CM, Zimmer BA, Koll NE, Bowrey HE, Aston-Jones G (2019) Increased 471 472 Number and Activity of a Lateral Subpopulation of Hypothalamic Orexin/Hypocretin Neurons 473 Underlies the Expression of an Addicted State in Rats. Biol Psychiatry 85:925-935. 474 475 Johanson CE, Balster RL, Bonese K (1976) Self-administration of psychomotor stimulant drugs: 476 the effects of unlimited access. Pharmacol Biochem Behav 4:45-51. 477 478 Knapp CM, Datta S, Ciraulo DA, Kornetsky C (2007) Effects of low dose cocaine on REM sleep 479 in the freely moving rat. Sleep Biol Rhythms 5:55-62. 480 481 McClung CA, Sidiropoulou K, Vitaterna M, Takahashi JS, White FJ, Cooper DC, Nestler EJ (2005) Regulation of dopaminergic transmission and cocaine reward by the Clock gene. Proc 482 483 Natl Acad Sci U S A 102:9377-9381. 484 485 McElhinny CJ, Jr., Lewin AH, Mascarella SW, Runyon S, Brieaddy L, Carroll FI (2012) 486 Hydrolytic instability of the important orexin 1 receptor antagonist SB-334867: possible 487 confounding effects on in vivo and in vitro studies. Bioorg Med Chem Lett 22:6661-6664. 488 489 Mucha RF, van der Kooy D, O'Shaughnessy M, Bucenieks P (1982) Drug reinforcement studied 490 by the use of place conditioning in rat. Brain Res 243:91-105. 491 492 Nomikos GG, Spyraki C (1988) Cocaine-induced place conditioning: importance of route of 493 administration and other procedural variables. Psychopharmacology (Berl) 94:119-125. 494 495 Puhl MD, Boisvert M, Guan Z, Fang J, Grigson PS (2013) A novel model of chronic sleep 496 restriction reveals an increase in the perceived incentive reward value of cocaine in high drug-497 taking rats. Pharmacol Biochem Behav 109:8-15. 498 499 Rao Y, Mineur YS, Gan G, Wang AH, Liu ZW, Wu X, Suyama S, de Lecea L, Horvath TL, 500 Picciotto MR, Gao XB (2013) Repeated in vivo exposure of cocaine induces long-lasting 501 synaptic plasticity in hypocretin/orexin-producing neurons in the lateral hypothalamus in mice. J 502 Physiol 591:1951-1966. 503 504 Roehrs T, Papineau K, Rosenthal L, Roth T (1999) Sleepiness and the reinforcing and 505 subjective effects of methylphenidate. Exp Clin Psychopharmacol 7:145-150. 506 507 Ritz MC, Lamb RJ, Goldberg SR, Kuhar MJ (1987) Cocaine receptors on dopamine transporters 508 are related to self-administration of cocaine. Science 237:1219-1223. 509 510 Sakurai T, Mieda M, Tsujino N (2010) The orexin system: roles in sleep/wake regulation. Ann N 511 Y Acad Sci 1200:149-161. 512

513 Sartor GC, Aston-Jones GS (2012) A septal-hypothalamic pathway drives orexin neurons,

514 which is necessary for conditioned cocaine preference. J Neurosci 32:4623-4631.

Sharf R, Guarnieri DJ, Taylor JR, DiLeone RJ (2010) Orexin mediates morphine place preference, but not morphine-induced hyperactivity or sensitization. Brain Res 1317:24-32. Shaw JK, Ferris MJ, Locke JL, Brodnik ZD, Jones SR, Espana RA (2017) Hypocretin/orexin knock-out mice display disrupted behavioral and dopamine responses to cocaine. Addict Biol 22:1695-1705. Spyraki C, Fibiger HC, Phillips AG (1982) Cocaine-induced place preference conditioning: lack of effects of neuroleptics and 6-hydroxydopamine lesions. Brain Res 253:195-203. Suchting R, Yoon JH, Miguel GGS, Green CE, Weaver MF, Vincent JN, Fries GR, Schmitz JM, Lane SD (2020) Preliminary examination of the orexin system on relapse-related factors in cocaine use disorder. Brain Res 1731:146359. Thannickal TC, John J, Shan L, Swaab DF, Wu MF, Ramanathan L, McGregor R, Chew KT, Cornford M, Yamanaka A, Inutsuka A, Fronczek R, Lammers GJ, Worley PF, Siegel JM (2018) Opiates increase the number of hypocretin-producing cells in human and mouse brain and reverse cataplexy in a mouse model of narcolepsy. Sci Transl Med 10. Tyree SM, Borniger JC, de Lecea L (2018) Hypocretin as a Hub for Arousal and Motivation. Front Neurol 9:413. Um HS, Kang EB, Koo JH, Kim HT, Jin L, Kim EJ, Yang CH, An GY, Cho IH, Cho JY (2011) Treadmill exercise represses neuronal cell death in an aged transgenic mouse model of Alzheimer's disease. Neurosci Res 69:161-173. Yoshida Y, Fujiki N, Nakajima T, Ripley B, Matsumura H, Yoneda H, Mignot E, Nishino S (2001) Fluctuation of extracellular hypocretin-1 (orexin A) levels in the rat in relation to the light-dark cycle and sleep-wake activities. Eur J Neurosci 14:1075-1081. Zachariou V, Caldarone BJ, Weathers-Lowin A, George TP, Elsworth JD, Roth RH, Changeux

Zachariou V, Caldarone BJ, Weathers-Lowin A, George TP, Elsworth JD, Roth RH, Changeux
 JP, Picciotto MR (2001) Nicotine receptor inactivation decreases sensitivity to cocaine.
 Neuropsychopharmacology 24:576-589.

583 584

591

561 Figure 1: A) Experimental timeline of cocaine CPP Study 1. B) Following conditioning to 8 mg/kg 562 cocaine, most animals undisturbed prior to cocaine conditioning trials spent more time in the 563 cocaine-paired side following conditioning as expected as compared to their pre-conditioning 564 test times (top), which shifted to all animals when SD occurred immediately prior to cocaine 565 conditioning trials (bottom). C) SD immediately prior to cocaine conditioning trials induced preference to 3 mg/kg cocaine and enhanced preference to 8 mg/kg cocaine without altering 566 567 preference to 15 mg/kg cocaine. SD in the absence of cocaine (0 mg/kg) did not induce 568 preference. Asterisks above columns indicate preference (as determined by a significant 569 difference from 0), the carrot between columns indicates a significant difference between 570 groups, and n.s. indicates a lack of significant difference between groups. 571

572 573 Figure 2: A) Experimental timeline for the cocaine CPP Study 2. B) Following conditioning to 8 574 mg/kg cocaine, most animals undisturbed prior to the post-conditioning test spent more time in 575 the cocaine-paired side as compared to their pre-conditioning test times (top), which shifted to a 576 higher proportion of animals when SD occurred immediately prior to the post-conditioning test 577 (bottom). C) SD immediately prior to post-conditioning test induced a non-significant trend 578 towards preference to 3 mg/kg cocaine and enhanced preference to 8 mg/kg cocaine, while 579 reducing preference to a non-significant trend to 15 mg/kg cocaine. Asterisks signs above 580 columns indicate preference (as determined by a significant difference from 0), the carrot 581 between columns indicates a significant difference between groups, and n.s. indicates a lack of 582 significant difference between groups.

585 586 Figure 3: A) Experimental timeline for the cocaine CPP Study 3. B) All animals spent more time 587 in the cocaine-paired side following conditioning as compared to their pre-conditioning test 588 values when Veh was administered prior to the cocaine trials (top) or when SB 334867 was 589 administered immediately following SD (bottom); however, only a subset of animals spent more 590 time in the cocaine-paired side when SB 334867 was administered in the absence of SD (right side). C) OX1R antagonism prior to cocaine conditioning trials blocked the SD-induced 592 preference to 3 mg/kg cocaine and the SD-induced enhanced preference to 8 mg/kg cocaine, 593 while OX1R antagonism in the absence of SD prevented the acquisition of preference to 8 594 mg/kg cocaine. Asterisks above columns indicate preference (as determined by a significant 595 difference from 0) and n.s. indicates a lack of significant difference between groups.

Figure 4: A) Experimental timeline for cocaine CPP Study 4. B) Most animals spent more time in the cocaine-paired side following conditioning as compared to their pre-conditioning test values both when undisturbed animals were administered SB 334687 prior to the post-conditioning test (top) and when sleep deprived animals were administered SB 334867 prior to the post-conditioning test (bottom). C) OX1R antagonism prevents the SD-induced increase in preference to 8 mg/kg cocaine, though both groups show preference for the cocaine-paired side. Asterisks above columns indicate preference (as determined by a significant difference from 0) and n.s. indicates a lack of significant difference between groups.

Figure 5: A) Dose response plot of preference from cocaine CPP Study 1 in which SD shifts the curve leftward (data replotted from Figure 1C). B) OX1R antagonism mitigates the SD-induced shift in the dose response curve (data replotted from Figures 1C & 3C). C) Dose response plot of preference from cocaine CPP Study 2 in which SD shifts the curve leftward, though to a lesser degree than under cocaine CPP Study 1 (data replotted from Figure 2C). D) The SD enhancement of relative preference, as determined by the ratio of average preference in SD and noSD groups (from Study 2) and indicated by >1 value (left bar), is blocked by OX1R antagonism (SD SB/noSD SB from Study 4; right bar). Notably, the relative preference of <1 under OX1R antagonism indicates that OX1R antagonism in the presence of SD reduces relative preference, while OX1R antagonism in the absence of SD increases relative preference.

4 Table 1: Cocaine CPP, Study 1

Study 1	0 mg	g/kg	3 mg/kg		
	noSD Sal, no SD SD Sal, noSD r		noSD Coc, SD	SD Coc, noSD	
	Sal	Sal	Sal	Sal	
Ν	12 12		10	11	
Mean+/-SEM	97.81+/-52.49 100.6+/-63.38		41.83+/-90.53	180.4+/-62.75	
95% CI	-17.73 to 213.4	-49.92 to 251.1	-163 to 246.6	40.56 to 320.2	
p value	0.09	0.17	0.655	0.0165	
Stat used for	Stat used for One sample T		One sample T	One sample T	
comparison	test	test	test	test	
	8 mg/kg		15 mg/kg		
	noSD Coc, SD	SD Coc, noSD	noSD Coc, SD	SD Coc, noSD	
	Sal Sal		Sal	Sal	
Ν	12 12		12	12	

Mean+/-SEM	126.4+/-83.62	348.7+/-62.95	257.9+/-65.4	284.9+/-94.67	
95% CI	-57.64 to 310.5	210.1 to 487.2	114 to 401.9	76.5 to 493.2	
p value	0.1588	0.0002	0.0023	0.0119	
Stat used for comparison	One sample T test	One sample T test	One sample T test	One sample T test	
group comparison	0 mg/kg	3 mg/kg	8 mg/kg	15 mg/kg	
Diff btw means	-2.521 ± 49.26	-138.5 ± 108.5	-222.3 ± 104.7	-26.93 ± 115.1	
95% CI	-104.7 to 99.63	-365.6 to 88.46	-439.3 to -5.173	-265.6 to 211.7	
p value	0.9596	0.11	0.0226	0.4085	
Stat used for comparison	Unpaired T test, two tailed	Unpaired T test, one tailed	Unpaired T test, one tailed	Unpaired T test, one tailed	

637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652

2 Table 2: Cocaine CPP, Study 2

	- ,	g/kg	8 mg/kg		15 mg/kg	
	noSD	SD	noSD	SD	noSD	SD
Ν	12	11	13	11	12	12
Mean+/-SEM	128.3+/- 76.91	187.4+/- 94.94	141.3+/- 49.55	256+/- 42.39	281.8+/- 72.06	179.6+/- 100.1
95% CI	-41.02 to 297.5	-24.19 to 398.9	33.35 to 249.3	161.6 to 350.5	123.2 to 440.4	-40.84 to 400
p value	0.1236	0.0767	0.0146	0.0001	0.0024	0.1005
Stat used for comparison	One sample T test					

group comparison	3 mg/kg	8 mg/kg	15 mg/kg
Diff btw means	-59.11 ± 121.3	114.7 ± 66.55	102.3 ± 123.4
95% CI	-311.3 to 193.1	-23.31 to 252.7	-153.6 to 358.1
p value	0.3155	0.0494	0.2081
Stat used for comparison	Unpaired T test, one tailed	Unpaired T test, one tailed	Unpaired T test, one tailed

677 Table 3: Cocaine CPP, Study 3


Study 3	3 mg/kg		8 mg/kg		
	noSD Veh	SD SB Coc,	noSD Veh	SD SB Coc,	noSD SB
	Coc, SD SB	noSD Veh	Coc, SD SB	noSD Veh	Coc, noSD
	Sal	Sal	Sal	Sal	Veh Sal
N	11 12		11	11	11
Mean+/-SEM	48.12+/- 70.25+/-		282+/-68.44	246.8+/-	141.8+/-
	48.24	93.15		37.69	102.1
95% CI	-59.36 to	-134.8 to	129.5 to	162.8 to	-85.82 to
	155.6	275.3	434.5	330.7	369.4
p value	0.342	0.4666	0.0021	<0.0001	0.1953


Stat used for comparison	One sample T test				
group comparison	3 mg/kg	8 mg/kg	8 mg/kg		
	noSD Veh	noSD Veh	noSD Veh		
	Coc, SD SB	Coc, SD SB	Coc, SD SB		
	Sal vs SD	Sal vs SD	Sal vs noSD		
	SB Coc,	SB Coc,	SB Coc,		
	noSD Veh	noSD Veh	noSD Veh		
	Sal	Sal	Sal		
Diff btw means	22.13 ±	35.25	140.2		
	107.8				
95% CI	-202.1 to	-211.9 to	-106.9 to		
	246.4	282.4	387.4		
p value	0.8394	0.9321	0.3467		
Stat used for	Unpaired T	One way	One way		
comparison	test, two	ANOVA with	ANOVA with		
	tailed	Sidak	Sidak		
		correction for	correction for		
		multiple	multiple		
		comparisons	comparisons		


Table 4: Cocaine CPP, Study 4


Study 4	8 mg/kg		
	noSD SB SD SB		
N	12 12		
Mean+/-SEM	237.4+/- 152.2+/-5 57.03		
95% CI	111.8 to 362.9	40.17 to 264.1	
p value	0.0016 0.0123		


Stat used for	One comple	One comple T
Stat used for	One sample	One sample T
comparison	T test	test
group comparison	8 mg/kg	
Diff btw means	-85.21 ±	
	76.42	
95% CI	-243.7 to	
	73.28	
p value	0.2769	
Stat used for	Unpaired T	
comparison	test, two	
•	tailed	



























Table 1: Cocalifie CPP, Study 1					
Study 1	0 mg	g/kg	3 m	g/kg	
	noSD Sal, no SD Sal	SD Sal, noSD Sal	noSD Coc, SD Sal	SD Coc, noSD Sal	
N	12	12	10	11	
Mean+/-SEM	97.81+/-52.49	100.6+/-63.38	41.83+/-90.53	180.4+/-62.75	
95% CI	-17.73 to 213.4	-49.92 to 251.1	-163 to 246.6	40.56 to 320.2	
p value	0.09	0.17	0.655	0.0165	
Stat used for comparison	One sample T test	One sample T test	One sample T test	One sample T test	
	8 mg	g/kg	15 m	ng/kg	
	noSD Coc, SD Sal	SD Coc, noSD Sal	noSD Coc, SD Sal	SD Coc, noSD Sal	
N	12	12	12	12	
Mean+/-SEM	126.4+/-83.62	348.7+/-62.95	257.9+/-65.4	284.9+/-94.67	
95% CI	-57.64 to 310.5	210.1 to 487.2	114 to 401.9	76.5 to 493.2	
p value	0.1588	0.0002	0.0023	0.0119	
Stat used for comparison	One sample T test	One sample T test	One sample T test	One sample T test	
group comparison	0 mg/kg	3 mg/kg	8 mg/kg	15 mg/kg	
Diff btw means	-2.521 ± 49.26	-138.5 ± 108.5	-222.3 ± 104.7	-26.93 ± 115.1	
95% CI	-104.7 to 99.63	-365.6 to 88.46	-439.3 to -5.173	-265.6 to 211.7	
p value	0.9596	0.11	0.0226	0.4085	
Stat used for comparison	Unpaired T test, two tailed	Unpaired T test, one tailed	Unpaired T test, one tailed	Unpaired T test, one tailed	

Table 1	I: Cocaine	CPP,	Study 1
---------	------------	------	---------

Table 2: Cocaine	CPP,	Study 2
------------------	------	---------

Study 2	3 mg/kg		8 mg/kg		15 mg/kg	
	noSD	SD	noSD	SD	noSD	SD
N	12	11	13	11	12	12
Mean+/-SEM	128.3+/-	187.4+/-	141.3+/-	256+/-	281.8+/-	179.6+/-
	76.91	94.94	49.55	42.39	72.06	100.1
95% CI	-41.02 to	-24.19 to	33.35 to	161.6 to	123.2 to	-40.84 to
	297.5	398.9	249.3	350.5	440.4	400
p value	0.1236	0.0767	0.0146	0.0001	0.0024	0.1005
Stat used for	One	One	One	One	One	One
comparison	sample T	sample T	sample T	sample T	sample T	sample T
	test	test	test	test	test	test
group	3 mg/kg		8 mg/kg		15 mg/kg	
comparison						
Diff btw means	-59.11 ± 121.3		114.7 ± 66.55		102.3 ± 123.4	
0.5% 01			00.041.050.7		450.01.050.4	
95% CI	-311.3 to 193.1		-23.31 to 252.7		-153.6 to 358.1	
p value	0.3155		0.0494		0.2081	
Stat used for	Unpaired T test, one		Unpaired T test, one		Unpaired T test, one	
comparison	tailed		tailed		tailed	

Table 3:	Cocaine	CPP,	Study 3
----------	---------	------	---------

Table 5. Cocaine CF F, Study 5					
Study 3	3 mg/kg			8 mg/kg	
	noSD Veh	SD SB Coc,	noSD Veh	SD SB Coc,	noSD SB
	Coc, SD SB	noSD Veh	Coc, SD SB	noSD Veh	Coc, noSD
	Sal	Sal	Sal	Sal	Veh Sal
Ν	11	12	11	11	11
Mean+/-SEM	48.12+/-	70.25+/-	282+/-68.44	246.8+/-	141.8+/-
	48.24	93.15		37.69	102.1
95% CI	-59.36 to	-134.8 to	129.5 to	162.8 to	-85.82 to
	155.6	275.3	434.5	330.7	369.4
p value	0.342	0.4666	0.0021	<0.0001	0.1953
Stat used for	One sample	One sample	One sample	One sample	One sample
comparison	T test	T test	T test	T test	T test
	I		I		
group comparison	3 mg/kg	8 mg/kg	8 mg/kg		
	noSD Veh	noSD Veh	noSD Veh		
	Coc, SD SB	Coc, SD SB	Coc, SD SB		
	Sal vs SD	Sal vs SD	Sal vs noSD		
	SB Coc,	SB Coc,	SB Coc,		
	noSD Veh	noSD Veh	noSD Veh		
	Sal	Sal	Sal		
Diff btw means	22.13 ±	35.25	140.2		
	107.8				
95% CI	-202.1 to	-211.9 to	-106.9 to		
	246.4	282.4	387.4		
p value	0.8394	0.9321	0.3467		
Stat used for	Unpaired T	One way	One way		
comparison	test, two	ANOVA with	ANOVA with		
	tailed	Sidak	Sidak		
		correction for	correction for		
		multiple	multiple		
		comparisons	comparisons		
	1		I	1	

Table 4: Cocaine CPP, Study 4

Study 4 8 mg/kg noSD SB SD SB N 12 12 Mean+/-SEM 237.4+/- 57.03 152.2+/- 57.03 50.88 95% CI 111.8 to 40.17 to 362.9 264.1 p value 0.0016 0.0123 One sample One sample comparison T test T test T test group comparison 8 mg/kg One sample T test 95% CI -243.7 to 73.28 P value 0.2769 Stat used for Unpaired T test, two T		,		
N 12 12 Mean+/-SEM 237.4+/- 57.03 152.2+/- 50.88 95% CI 111.8 to 362.9 40.17 to 264.1 p value 0.0016 0.0123 Stat used for comparison One sample T test One sample T test group comparison 8 mg/kg Diff btw means -85.21 ± 76.42 95% CI -243.7 to 73.28 p value 0.2769 Stat used for Unpaired T	Study 4	8 mg/kg		
Mean+/-SEM 237.4+/- 57.03 152.2+/- 50.88 95% CI 111.8 to 362.9 40.17 to 264.1 p value 0.0016 0.0123 Stat used for comparison One sample T test One sample T test group comparison 8 mg/kg Diff btw means -85.21 ± 76.42 95% CI -243.7 to 73.28 p value 0.2769 Stat used for Unpaired T		noSD SB	SD SB	
57.03 50.88 95% CI 111.8 to 40.17 to 362.9 264.1 p value 0.0016 0.0123 Stat used for comparison One sample T test One sample T test group comparison 8 mg/kg Diff btw means -85.21 ± 76.42 95% CI -243.7 to 73.28 p value 0.2769 Stat used for Unpaired T	N	12	12	
95% CI 111.8 to 362.9 40.17 to 264.1 p value 0.0016 0.0123 Stat used for comparison One sample T test One sample T test group comparison 8 mg/kg Diff btw means -85.21 ± 76.42 95% CI -243.7 to 73.28 p value 0.2769 Stat used for Unpaired T	Mean+/-SEM	237.4+/-	152.2+/-	
362.9 264.1 p value 0.0016 0.0123 Stat used for comparison One sample T test One sample T test group comparison 8 mg/kg Diff btw means -85.21 ± 76.42 -243.7 to 73.28 p value 0.2769 -2769 Stat used for Unpaired T		57.03	50.88	
p value0.00160.0123Stat used for comparisonOne sample T testOne sample T testgroup comparison8 mg/kgDiff btw means-85.21 ± 76.4295% CI-243.7 to 73.28p value0.2769Stat used forUnpaired T	95% CI	111.8 to	40.17 to	
Stat used for comparisonOne sample T testOne sample T testgroup comparison8 mg/kgDiff btw means-85.21 ± 76.4295% Cl-243.7 to 73.28p value0.2769Stat used forUnpaired T		362.9	264.1	
comparisonT testT testgroup comparison8 mg/kgDiff btw means-85.21 ± 76.4295% CI-243.7 to 73.28p value0.2769Stat used forUnpaired T	p value	0.0016	0.0123	
group comparison 8 mg/kg Diff btw means -85.21 ± 76.42 95% Cl -243.7 to 73.28 p value 0.2769 Stat used for Unpaired T	Stat used for	One sample	One sample	
Diff btw means -85.21 ± 76.42 95% CI -243.7 to 73.28 p value 0.2769 Stat used for Unpaired T	comparison	T test	T test	
Diff btw means -85.21 ± 76.42 95% CI -243.7 to 73.28 p value 0.2769 Stat used for Unpaired T				
76.42 95% CI -243.7 to 73.28 p value 0.2769 Stat used for Unpaired T	group comparison	8 mg/kg		
95% CI -243.7 to 73.28 p value 0.2769 Stat used for Unpaired T	Diff btw means	-85.21 ±		
73.28 p value 0.2769 Stat used for Unpaired T		76.42		
p value0.2769Stat used forUnpaired T	95% CI	-243.7 to		
Stat used for Unpaired T		73.28		
	p value	0.2769		
comparison test, two	Stat used for	Unpaired T		
	comparison	test, two		
tailed		tailed		